https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/cannabidiol-trial-shows-reduction-seizures-children-dravet-syndrome/
Cannabidiol trial shows reduction in seizures for children with Dravet syndrome
30 May 2017, 12:58 p.m.
A trial conducted in Europe and the USA has shown that cannabidiol – a drug derived from cannabis but with the psycho-active elements removed – reduces seizures in children with a form of drug resistant epilepsy, known as Dravet syndrome.
The study was led by NIHR GOSH BRC cross cutting theme lead Professor Helen Cross, in collaboration with New York University.
In the trial one hundred and twenty children with Dravet syndrome across Europe and the USA were given two daily doses of cannabidiol orally for fourteen weeks. At the end of the study the average number of severe seizures reduced by nearly 40%. For 5% of patients, seizures stopped completely.
The research, Trial of Cannabidiol for Drug-Resistant seizures in the Dravet Syndrome, was published in the New England Journal of Medicine.
Read the press release.
What do bush babies, tamarin monkeys, and mouse lemurs have that humans don’t?
GOSH imaging researchers have worked with teams in Harvard in the USA to work out how and when our pelvises developed to be different from other animals.
Nanodiamonds and hormones used in rare condition to promote lung growth
An international research team led by GOSH, UCL and KU Leuven in Belgium, is using 3D-printing and nanodiamonds, to design treatments that could help babies repair their damaged lungs in the womb.
New national registry for inherited hearing loss
A new national registry is helping researchers understand more about inherited hearing loss – and could help bring about new treatments.
Teenager off to university after life-changing gene therapy
A teenager with a rare, life-limiting genetic condition is off to university after receiving a gene therapy that changed his life.